CEQUA (ciclosporin), an aqueous, nanomicellar ophthalmic ciclosporin solution is now listed on the PBS for patients living with chronic, severe dry eye disease with keratitis.
It is indicated for increasing tear production in moderate-to-severe dry eye disease, where prior use of artificial tears has not been sufficient.
Cequa's delivery system improves the ciclosporin's bioavailability, and enables a more than 10-fold increase in aqueous solubility, compared with a 0.05% ciclosporin ophthalmic emulsion, says its manufacturer, Sun Pharma.
Cequa inhibits T-cell activation and reduces inflammation associated with dry eye disease.
Two clinical studies, OTX-101-2014-0017 and OTX-101-2016-0018, demonstrated significantly reduced signs of dry eye disease rapidly, with noticeably reduced corneal staining at 28 days, and reduced conjunctival staining at 56 days, explained its maker.
Cequa's long-term safety is supported with the most common, adverse event being mildly transient instillation site pain, its manufacturer said.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Jun 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Jun 23
